Expert Insights On Downstream Bioprocessing

71. 6 PEG Alternatives You Should Be Thinking About 11/22/2023

    PEGylation is a common way to minimize off-target effects and general toxicity, but it also poses life-threatening risks because it prolongs the drug's time in the bloodstream. Scientists are exploring these alternatives to combat the risk.

72. Building AAV Manufacturing Capacity For Large Patient Diseases 11/15/2023

    AAV-based gene therapies are poised to treat larger patient populations with diseases like cardiovascular and neurological conditions. But scaling poses safety and manufacturing challenges. This deep dive into the issues could help companies clear away some of those obstacles. 

73. Understanding The Importance Of Real-Time Monitoring For Protein Aggregation 10/30/2023

    This article breaks down the advantages of real-time monitoring for protein therapeutics, including how it can accelerate timelines, produce better data, and smooth regulatory compliance.

74. FDA Sets Recommendations For Predicting Dangerous Nitrosamine Impurities 10/25/2023

    The FDA recently published a final guidance that sets a recommended framework for predicting the potential of nitrosamine drug substance-related impurities.

75. Opportunities For AI To Assist Cell & Gene Therapy Companies 10/10/2023

    Although AI/ML is still in a nascent stage in the cell and gene therapy sector, it has an enormous amount of potential to transform overall business models, early R&D, clinical trials, manufacturing and operations, and regulatory compliance support in these key ways.

76. Preformulation Of Excipients In Biologics Development 9/28/2023

    Most of the instability problems of a drug product come from excipients, in particular, they come from impurities in excipients. Those issues are best cleaned up in the preformulation period to determine excipient compatability.

77. Guidelines For mRNA Drug Product Manufacturing And Quality Control 9/15/2023

    The lightning fast rise of mRNA raised the need for manufacturing standards and consensus on product quality attributes and test methods. This article provides perspective and insight on PQAs for mRNA vaccines and other mRNA-based products.

78. How To Implement Size Exclusion Chromatography And Mitigate HCP Risk 9/13/2023

    Research shows size-exclusion chromatography improves the host cell protein detection capabilities of liquid chromatography-tandem mass spectrometry. This guest article explores the strategy of using both to better understand HCP persistence in the purification process.

79. Comparing Alternative Viral Vector Purification Tech 8/25/2023

    Clarification of viral vector harvests is more complicated than mAb clarification. But, as with mAbs, the technology is advancing at a rapid clip. In part 2 of this series on modern purification technology, expert Jack Vicalvi discusses process schemes used for clarifying different types of viral vector therapeutics.

80. Comparing Alternative mAb Purification Tech 8/21/2023

    The science of purifying monoclonal antibodies has come a long way, and drugmakers have far more technology to choose from. Expert Jack Vicalvi explains the advantages of modern techniques, how they're different from traditional methods, and how they fit into overall process schemes.